Singh Fiza, Weinberg Jeffrey M
Department of Dermatology, ST. Luke's-Roosevelt Hospital Center, New York, New York 10025, USA.
J Drugs Dermatol. 2004 Mar-Apr;3(2):141-3.
Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population. Over the last several years, one of the major focuses in psoriasis research has been the development of novel biologic therapies for this disease. The aim of these therapies is to provide selective, immunologically directed intervention, with the hope that such specificity will result in fewer side effects than traditional therapies. In addition to these therapies, there are also oral medications in development for psoriasis. The goal of this article is to review oral tazarotene, a novel retinoid, and oral pimecrolimus, a novel macrolactam therapy, for the treatment of moderate to severe psoriasis.
银屑病是一种慢性皮肤病，影响着约2%的美国和欧洲人口。在过去几年中，银屑病研究的主要重点之一是开发针对该疾病的新型生物疗法。这些疗法的目的是提供选择性的、免疫导向的干预，希望这种特异性将导致比传统疗法更少的副作用。除了这些疗法外，也有正在研发的用于治疗银屑病的口服药物。本文的目的是综述新型维甲酸类药物口服他扎罗汀和新型大环内酰胺类疗法口服吡美莫司治疗中重度银屑病的情况。
